Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/s41598-021-90348-7 http://scihub22266oqcxt.onion/10.1038/s41598-021-90348-7 34040046!8155001!34040046     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Sci+Rep 2021 ; 11 (1): 11046 Nephropedia Template TP {{tp|p=34040046|t=2021. Novel human neutralizing mAbs specific for Spike-RBD of SARS-CoV-2 |pdf=|usr=}}{{34040046}} gab.com Text Novel human neutralizing mAbs specific for Spike-RBD of SARS-CoV-2 JO: Sci Rep http://www.kidney.de/pget.php?&tw=1&pmid=34040046 #FOAvip Among the therapies against the pandemic SARS-CoV-2 virus, monoclonal Antibodies (mAbs) targeting the Spike glycoprotein represent good candidates to interfere in the Spike/ACE2 interaction, preventing virus cell entry. Since anti-spike mAbs, used individually, might be unable to block the virus entry in the case of resistant mutations, we designed an innovative strategy for the isolation of multiple novel human scFvs specific for the binding domain (RBD) of Spike. By panning a large phage display antibody library on immobilized RBD, we obtained specific binders by eluting with ACE2 in order to identify those scFvs recognizing the epitope of Spike interacting with its receptor. We converted the novel scFvs into full size IgG4, differently from the previously isolated IgG1 mAbs, to avoid unwanted potential side effects of IgG1 potent effector functions on immune system. The novel antibodies specifically bind to RBD in a nanomolar range and interfere in the interaction of Spike with ACE2 receptor, either used as purified protein or when expressed on cells in its native conformation. Furthermore, some of them have neutralizing activity for virus infection in cell cultures by using two different SARS-CoV-2 isolates including the highly contagious VOC 202012/01 variant and could become useful therapeutic tools to fight against the SARS-CoV-2 virus. Twit Text FOAVip Novel human neutralizing mAbs specific for Spike-RBD of SARS-CoV-2 ????Sci Rep http://www.kidney.de/pget.php?&tw=1&pmid=34040046 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34040046 #FOAvip English Wikipedia <ref>{{Cite pmid|34040046}}</ref> Novel human neutralizing mAbs specific for Spike-RBD of SARS-CoV-2 #MMPMID34040046 Passariello M; Gentile C; Ferrucci V; Sasso E; Vetrei C; Fusco G; Viscardi M; Brandi S; Cerino P; Zambrano N; Zollo M; De Lorenzo C Sci Rep 2021[May]; 11 (1): 11046 PMID34040046show ga Among the therapies against the pandemic SARS-CoV-2 virus, monoclonal Antibodies (mAbs) targeting the Spike glycoprotein represent good candidates to interfere in the Spike/ACE2 interaction, preventing virus cell entry. Since anti-spike mAbs, used individually, might be unable to block the virus entry in the case of resistant mutations, we designed an innovative strategy for the isolation of multiple novel human scFvs specific for the binding domain (RBD) of Spike. By panning a large phage display antibody library on immobilized RBD, we obtained specific binders by eluting with ACE2 in order to identify those scFvs recognizing the epitope of Spike interacting with its receptor. We converted the novel scFvs into full size IgG4, differently from the previously isolated IgG1 mAbs, to avoid unwanted potential side effects of IgG1 potent effector functions on immune system. The novel antibodies specifically bind to RBD in a nanomolar range and interfere in the interaction of Spike with ACE2 receptor, either used as purified protein or when expressed on cells in its native conformation. Furthermore, some of them have neutralizing activity for virus infection in cell cultures by using two different SARS-CoV-2 isolates including the highly contagious VOC 202012/01 variant and could become useful therapeutic tools to fight against the SARS-CoV-2 virus. |Angiotensin-Converting Enzyme 2/metabolism[MESH] |Antibodies, Monoclonal[MESH] |Antibodies, Neutralizing/genetics/immunology/*metabolism[MESH] |Antibodies, Viral/genetics/immunology/*metabolism[MESH] |COVID-19/immunology/*therapy[MESH] |Cells, Cultured[MESH] |Epitopes[MESH] |Humans[MESH] |Immunoglobulin G/immunology/*metabolism[MESH] |Immunotherapy/*methods[MESH] |Pandemics[MESH] |Protein Binding[MESH] |Protein Domains/genetics[MESH] |SARS-CoV-2/*physiology[MESH]Novel human neutralizing mAbs specific for Spike-RBD of SARS-CoV-2 (epmc).pdf DeepDyve Pubget Overpricing